Opus Genetics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Plans
On September 10, 2026, Dr. George Magrath, the Company’s Chief Executive Officer, terminated the Rule 10b5-1 trading plan previously adopted on June 5, 2026.
On September 22, 2026, Dr. Sally Tucker, the Company’s Chief Medical Officer, terminated the Rule 10b5-1 trading plan previously adopted on May 1, 2026 and adopted a new Rule 10b5‑1 trading plan (as defined in Rule 10b5‑1(c) under the Securities Exchange Act of 1934) providing for the potential sale of up to 191,316 shares of the Company’s common stock. Pursuant to the new trading plan, sales of shares may commence on or after October 23, 2026, and are scheduled to terminate on or prior to May 31, 2028, subject to earlier termination in accordance with its terms.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.